By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Life science startups face a myriad of unique challenges due to the complexity of the healthcare system, including potentially years-long paths to market, regulatory hurdles, and possible reimbursement issues. All of these areas, among others, present opportunities for service providers to lend their expertise, preventing startups from costly mistakes that could prevent their products from reaching the market due to reasons other than a failure in the technology.

While connecting startups with investors is a large part of our work, Life Science Nation has also emphasized the importance of the presence of service providers at our Redefining Early Stage Investment (RESI) conferences.  RESI’s unique partnering platform allows attendees to filter the companies by sector, indication, and stage of development, among other criteria, so your target leads will be just a few clicks away.

While RESI partnering provides a powerful avenue to identify new clients, service providers that attend RESI have the option of multiple levels of participation, improving their exposure beyond that generated by partnering outreach. This can include:

Hosting a 1-hour live workshop to introduce your service

• Open to all registered RESI attendees
• The recording will be posted on the sponsor dedicated webpage (a virtual exhibition table) at RESI live agenda for a month, during which you can expect some attendees to contact you in partnering (Check Out an Example Here: McDermott Will & Emery)
• After the conference, a detailed report on the workshop audience will be provided

Get a spotlight on Life Science Nation’s Weekly Newsletter, with a readership of 50,000+

• Newsletter Interview: Tell our readers more about your services/products or provide sights on a related topic in the format of podcase or article (Learn more about a recent workshop in a newsletter article)
• Newsletter Banner Ad: feature your brand logo and website

Interested in learning more about the opportunities available at RESI? Make sure to check out the full sponsorship brochure below!

By Rory McCann, Marketing Manager & Conference Producer, LSN

It seems like not much time has passed since events around the world opened back up for in-person attendance. However, with the emergence and spread of the Omicron variant of COVID-19, many who had enthusiastically jumped back into in-person networking are asking, “What now?”

Whether discussing COVID-19 or fundraising in general, there is no crystal ball, leaving many to wander around in the dark hoping to make the most of uncertain times. In the absence of future forecasting, what I can offer instead are principles of partnering that are consistent and productive, no matter the state of the world around you.

Partnering is a numbers game, but not one of luck. Success takes research, strategy, patience, follow-up, and the ability to take feedback constructively. To prove that these aren’t new principles, check out these past interviews and articles outlining what successful partnering looks like. The truth is that there is no perfect environment for fundraising. Whether the Omicron variant throwing a wrench into the best-laid plans of in-person meetings or another event that gets in the way, solid principles will carry into successful partnering and lead to powerful partnerships in the future.

• Embracing the Early-Stage Journey
• Does RESI Work?
• Telling Your Story
• Getting it Right from Pitch to Partner
• Getting Ready for Successful Partnering Meetings
• Nailing the Digital Handshake for Online Investor Meetings
• How to Fail
• The Lost Art of Following Up
• What Successful Partnering Really Looks Like

Learn more about how Life Science Nation can help you with your fundraising efforts and check out the newest digital  Redefining Early Stage Investment (RESI) conference, January 11-13. Early bird rates apply until December 17!

A healthcare investment firm based in the USA with multiple billion dollars in assets under management. The firm invests in life science companies and is currently investing out of its fifth fund. The firm looks to invest in companies globally, with a focus on companies located in the United States.

The firm is interested in therapeutics, medical devices and diagnostics, although the majority of the firm’s investments have been in the therapeutics space. The firm is primarily interested in Series A, B, and C opportunities, with a focus on therapeutics that have strong preclinical data or are peri-clinical. The firm also has special interests in oncology, infectious diseases, rare diseases, dermatology and autoimmune disorders.

The firm is looking for companies with significant competitive advantage and strong, experienced management teams. The firm is willing to invest in both publicly and privately held companies. The firm is open to both lead and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a venture fund based in San Diego, California, founded in 2021. The firm has $750 AUM for their first fund and will invest from early to later stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $10M or more, but may participate in earlier rounds, primarily as a fund of funds. The firm will invest globally, and prefers companies developing platform technologies or with multiple assets.

Within therapeutics, the firm is interested in small molecules, biologics and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases. The firm is willing to invest from pre-IND all the way to PIPEs.

The firm is willing to lead or co-invest, but is a very active investor, and will take at least one board seat after investment. As an individual investor, the firm prefers to invest at least $10M per company, but may invest in smaller rounds as an LP of another investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

By Karen Deyo, Director of Investor Research, Israel BD, LSN

As many around the world prepare for a litany of winter holidays celebrated globally, the early-stage life science and healthcare world enthusiastically awaits the start of their own winter festival: JPM Week. Whether virtual, in-person, or hybrid, events associated with JPM Week are expected to fill up with buyers and sellers seeking connections and to make deals.

At Digital RESI JPM, attendees can expect an agenda packed with investor panel discussions, insightful tales from the road from successful entrepreneurs, pitch sessions, educational workshops, and more – all designed to help the early-stage entrepreneur understand their audience and make the connections that best match their product and stage of development. Check out the Digital RESI JPM agenda below and sign up by December 17 to save $200!

	Tuesday (1/11)	Wednesday (1/12)	Thursday (1/13)
10AM EST	Innovator’s Pitch Challenge #1	Family Offices Panel	Innovator’s Pitch Challenge #8
		Innovator’s Pitch Challenge #5
11AM EST	Medical Devices Investor Panel	Defining and Funding Age-Tech Innovations Panel	Diagnostics Investor Panel
12PM EST	Workshop (TBD)	Workshop (TBD)	Workshop (TBD)
1PM EST	Innovator’s Pitch Challenge #2	Innovator’s Pitch Challenge #6	Innovator’s Pitch Challenge #9
2PM EST	The Regulatory Pathway for AI in Healthcare Panel	Digital Health Investor Panel	Emerging Products and Technologies for Aging at Home Panel
3PM EST	Big Pharma Panel	The Early Stage Pivot Panel	Corporate VC Panel
	Innovator’s Pitch Challenge #3		Innovator’s Pitch Challenge #10
4PM EST	Tales from the Road: Age-Tech Innovators on their Fundraising Journey	Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey	Tales from the Road: AI Innovators on their Fundraising Journey
5PM EST	Longevity Investors Share Their Investment Thesis	Longevity Entrepreneurs Discuss Their New Products	Innovator’s Pitch Challenge #11
	Innovator’s Pitch Challenge #4	Innovator’s Pitch Challenge #7

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Last month, Life Science Nation wrapped up its final Innovator’s Pitch Challenge (IPC) of the year. While the team is busy preparing for our next one at JPM Week, January 11-13, we would be remiss not to announce and celebrate the winners of the Digital RESI November IPC!

1st Place Sana Health	2nd Place Braingrade	3rd Place MOWOOT

Learn more about our winners and how they are shaping the early-stage ecosystem with their technology. Winners are chosen by the votes of our attendees who can access their dedicated landing pages and pitch materials, as well as participate in the live Q&A session. If you’re interested in joining the next IPC, applications are open until December 17. Applications are accepted on a rolling basis, so send yours in today!

FDA Breakthrough device designation for fibromyalgia (class II), Sana is an audiovisual neuormodulation device that gives anxiety relief on demand, giving it applications across pain, mental health and long covid. We have recently completed a pivotal study in Fibromyalgia with Duke, which will be submitted to the FDA as a Denovo in the next month. We also have a pivotal study underway in Neuropathic pain at Mount Sinai, and two more pivotals in Anxiety and PTSD due to start in Q1. We recently were awarded a DoD grant for PTSD. We are on market under a 513g Designation as a wellness device, allowing for speedy clinical trials and adoption. Future areas – depression, lower back pain and long covid. The user puts on the device, and pulses of light and sound induce deep relaxation or sleep within 16 minutes.

Braingrade is developing a brain co-processor, the next-generation brain-machine interface to enhance human cognition. As it?s first indication, the company is targeting Alzheimer?s Disease (AD). The Braingrade memory implant is a fully implantable (invisible, under the skin) deep brain stimulator. The device is capable of detecting abnormal neural activity across multiple brain regions and applying AI-optimized, patterned, electrical stimulation to rectify affected memory circuit oscillations and restore healthy brain activity. It does this through novel probes that use a new material allowing more electrodes at a smaller scale. Braingrade is comprised of a team of experts in all facets of neuro-engineering, with a proven track record of collectively developing and commercialising neuromodulation devices and includes executives and founders of Neuralink, Paradromics & Blackrock as well as DARPA Scientists.

MOWOOT is a growth stage medical device company treating intestinal transit disorders with a novel, purely physical, non-drug, non-invasive solution.